Lilly Brings 21 Dermatology Posters to Fall Clinical 2026
Lilly Brings 21 Dermatology Posters to Fall Clinical 2026
Eli Lilly and Company presented a broad dermatology research programme at the Fall Clinical Dermatology Conference 2026, featuring 21 poster presentations focused on chronic inflammatory skin conditions. The programme covered atopic dermatitis, psoriasis and alopecia areata, highlighting research into sustained disease control, treatment experience, pediatric outcomes and the relationship between psoriasis and obesity.
The conference took place in Las Vegas from October 8 to 11, with Lilly announcing its planned presentations on October 5. The programme featured data related to EBGLYSS (lebrikizumab), Taltz (ixekizumab), Zepbound (tirzepatide) and Olumiant (baricitinib). Source: Lilly announcement
EBGLYSS Research Leads the Atopic Dermatitis Programme
EBGLYSS accounted for 13 of Lilly’s 21 planned posters. The presentations explored disease control, maintenance dosing, topical treatment use and outcomes among different patient populations living with moderate-to-severe atopic dermatitis.
The programme also included findings from studies evaluating lebrikizumab in patients with disease affecting high-impact areas, including the hands, feet and face. These areas can present particular challenges because symptoms may interfere with everyday activities.
Pediatric Research Expands the Evidence Base
Lilly also highlighted investigational efficacy and safety findings from the Phase 3 ADorable-1 study in pediatric patients aged six months and older with moderate-to-severe atopic dermatitis. The presentations covered results through Week 16, including itch, sleep and safety outcomes.
These findings were presented as clinical research rather than confirmation of an expanded regulatory indication. The company’s announcement stated that the pediatric data were investigational, and treatment eligibility remains dependent on the applicable approved product information.
Taltz and Zepbound Explore the Link Between Psoriasis and Obesity
Six presentations examined the concomitant use of Taltz and Zepbound in people with psoriasis and overweight or obesity. This research addresses the overlap between inflammatory skin disease and metabolic health.
The programme included exploratory biomarker findings from the TOGETHER-PsO study involving adults with moderate-to-severe plaque psoriasis and overweight or obesity, alongside at least one weight-related comorbid condition.
The analysis aimed to improve understanding of the immunometabolic biology connecting these conditions and assess how adding tirzepatide to ixekizumab may affect biological markers compared with ixekizumab alone. Other presentations examined cardiovascular risk factors, patient experiences, cost-effectiveness and subgroup outcomes.
These analyses may help researchers better understand how skin inflammation and metabolic health interact. However, exploratory biomarker results should not be interpreted as proof that a particular combination will benefit every patient or replace individualized medical assessment.
Olumiant Data Focus on Long-Term Outcomes in Alopecia Areata
Lilly’s programme also included long-term findings for Olumiant in adolescents aged 12 and older with severe alopecia areata, an autoimmune condition that can cause significant hair loss.
Data from the BRAVE-AA-PEDS Phase 3 trial examined sustained treatment effects through 1.5 years and safety outcomes over a maximum treatment period of 2.5 years. The study was designed specifically to evaluate pediatric patients with severe alopecia areata.
The presentations add to the evidence being developed around long-term treatment outcomes in younger patients. As with other medicines affecting immune pathways, treatment decisions require consideration of approved indications, potential risks and individual patient circumstances.
Research Programme Covers Disease Control, Safety and Treatment Experience
Across the 21 posters, Lilly’s programme addressed several practical questions in dermatology research:
Disease control: whether improvements can be maintained over time and whether less frequent maintenance dosing may be appropriate for eligible patients.
Treatment burden: changes in itch, sleep, quality of life, flare rates and reliance on topical therapies.
Pediatric evidence: efficacy and safety findings in younger patients with atopic dermatitis and adolescents with severe alopecia areata.
Comorbidities: the relationship between psoriasis, obesity and broader metabolic health.
Real-world outcomes: treatment persistence, patient experiences and patterns of care beyond controlled clinical trials.
Together, these topics reflect a wider industry focus on evaluating treatment performance across clinical trials, real-world practice and patient-relevant outcomes.
Implications for Dermatology Research
Lilly’s Fall Clinical 2026 programme illustrates how dermatology development is increasingly addressing more than visible skin symptoms alone. Research is also examining long-term disease control, treatment schedules, pediatric populations and the interaction between inflammatory skin disorders and other health conditions.
The findings may inform future research and clinical discussions, although the significance of each presentation depends on its study design, population, follow-up period and full results. Poster presentations do not by themselves establish new treatment recommendations or regulatory approvals.
For dermatology researchers and healthcare professionals, the programme provides a snapshot of Lilly’s ongoing work across atopic dermatitis, psoriasis and alopecia areata, with particular attention to sustained outcomes and the complexity of chronic inflammatory disease.
Sources:
Coconut Oil
Found this useful?
